Discovery of 1-(Phenylsulfonyl)-1,2,3,4-tetrahydroquinoline Derivative as Orally Bioavailable and Safe RORγt Inverse Agonists for Potential Treatment of Rheumatoid Arthritis
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01727 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Shan-Liang Sun und 29 weiteren Autor:innen. Beteiligte Einrichtung: National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collab…. Hauptthemen laut MEDLINE: Nuclear Receptor Subfamily 1, Group F, Member 3, Quinolines, Biological Availability, Arthritis, Rheumatoid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Major Research Plan, Government of Jiangsu Province, Natural Science Foundation of Jiangsu Provincial Colleges and Universities.
Abstract (Originalsprache)
The retinoic acid receptor-related orphan receptor γt (RORγt) is a key regulator of Th17 cells, associated with autoimmune diseases, making it a significant drug target. Herein, we designed and synthesized 1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinoline derivatives, improving upon GSK2981278 to enhance bioavailability. Of which, D4 exhibited superior bioavailability (F = 48.1 and 32.9% in mice and rats, respectively) compared to GSK2981278 (F = 6.2 and 4.1%, respectively), and effectively treated psoriasis in mice at lower doses. Moreover, for the first time, we report the efficacies of a RORγt inverse agonist in mouse models of rheumatoid arthritis. (R)-D4, the eutomer of D4, matched or exceeded GSK2981278's therapeutic effects at lower doses, with no adverse effects observed after 2 weeks of administration. These results position (R)-D4 as a promising and orally bioavailable candidate for Th17-mediated autoimmune disease treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrializa…
- R&D Institute, Chia Tai Tianqing Pharmaceutical Group Co., LTD, Nanjing 211122, China.
- R&D Center, Gear Pharma, Nanjing 210000, China.
- The Research Center of Chiral Drugs, Innovation Research Institute of Traditional Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
- Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, Nanjing 211198, China.
ORCID-Profile: Yan-Cheng Yu, Xin Xue, Nian-Guang Li, Xiao-Long Wang
Förderung
- Major Research Plan
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Provincial Colleges and Universities
Zitieren
APA
Sun, S. L., Xu, H. J., Jiang, X. L., Zhou, J., Shi, W., Wang, X. J., Song, W., Chang, X. Y., Ma, X. Q., Zou, X. F., Wu, S. H., Yang, J., Li, Q. Q., Wang, Z. X., Cai, J., Yu, S. P., Wang, Q. X., Wei, T. H., Wu, J. Z., …, & Wang, X. L. (2024). Discovery of 1-(Phenylsulfonyl)-1,2,3,4-tetrahydroquinoline Derivative as Orally Bioavailable and Safe RORγt Inverse Agonists for Potential Treatment of Rheumatoid Arthritis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01727
Vancouver
Sun SL, Xu HJ, Jiang XL, Zhou J, Shi W, Wang XJ, et al. Discovery of 1-(Phenylsulfonyl)-1,2,3,4-tetrahydroquinoline Derivative as Orally Bioavailable and Safe RORγt Inverse Agonists for Potential Treatment of Rheumatoid Arthritis. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01727
BibTeX
@article{Sun2024,
author = {Sun, Shan-Liang and Xu, Hong-Jiang and Jiang, Xiao-Long and Zhou, Jian and Shi, Wei and Wang, Xiao-Jin and Song, Wei and Chang, Xia-Yun and Ma, Xue-Qin and Zou, Xiao-Fang and Wu, Shi-Han and Yang, Jin and Li, Qing-Qing and Wang, Zi-Xuan and Cai, Jiao and Yu, Shao-Peng and Wang, Qing-Xin and Wei, Tian-Hua and Wu, Jia-Zhen and Tong, Zhen-Jiang and Zhou, Yun and Wang, Yi-Bo and Yu, Yan-Cheng and Leng, Xue-Jiao and Ding, Ning and Shi, Zhi-Hao and Dai, Wei-Chen and Xue, Xin and Li, Nian-Guang and Wang, Xiao-Long},
title = {Discovery of 1-(Phenylsulfonyl)-1,2,3,4-tetrahydroquinoline Derivative as Orally Bioavailable and Safe RORγt Inverse Agonists for Potential Treatment of Rheumatoid Arthritis},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01727}
}
EUVIMED